Recent Case Studies
Case Study
Phase 3 Flu Vaccine Program
Tekton coordinated startup and recruitment across seven sites in three states for this vaccine program, which encompassed several studies. The program culminated in FDA product approval.
- All 7 Tekton sites exceeded their initial enrollment goals
- 169% of the combined initial enrollment goal was achieved
- 1,500+ participants randomized across the program
- 340+ participants randomized at the Austin site
Case Study
Type 1 Diabetes Trial
Across three Texas sites, Tekton used physician-led database review and detailed prescreening to focus outreach on likely-qualified participants.
- All Tekton sites exceeded their initial enrollment goals
- 170% average enrollment across 3 sites
- 1-day average regulatory turnaround across sites
- McKinney reached more than 200% of its initial goal and moved from activation to FPV in 4 days
Case Study
Phase 3 GLP-1 Study
Lacy Anderson, MD, led this Phase 3 GLP-1 study at Tekton’s Moore, OK, site.
- 1-day regulatory receipt-to-submission turnaround
- First participant visit in under 24 hours after activation
- Enrollment goal met 3 months early
Case Study
Alzheimer's Disease Trial
Tekton onboarded and supported a new Principal Investigator while also contributing to study design and implementation.
- First participant randomized in the study
- 110% of the initial enrollment goal achieved
- One of the study’s top-enrolling sites
Case Study
CGM Device Study
Tekton’s Wichita, KS, site used personalized outreach to a pre-identified patient pool for this study involving pregnant participants with diabetes.
- 240% of the initial enrollment goal achieved
- 100% participant retention
- 2-day regulatory turnaround
Case Study
Phase 2 Migraine Study
Robert Lockwood, MD, led this Phase 2 migraine study at Tekton’s former Yukon, OK, location, now Oklahoma City.
- Enrollment goal met ahead of schedule
- First participant visit within 48 hours of activation
- 1.5 days from regulatory receipt to submission
- 100% participant retention and near-perfect eDiary compliance
More Case Studies
-
Delivering 240% of Enrollment Goal With 100% Retention in a CGM Study
Tekton’s Wichita, Kansas site supported a continuous glucose monitoring device trial involving participants with gestational, type 1, and type 2 diabetes. Personalized outreach to a pre-identified patient pool helped the … Read more
-
Randomizing the First Participant and Reaching 110% of Goal for an Alzheimer’s Study
Tekton supported a one-site Alzheimer’s disease trial led by a recently trained and onboarded new-to-Tekton Principal Investigator. Tekton also consulted on study design and implementation. The site randomized the study’s … Read more
-
Reaching 120% of Enrollment Goal Across Five Adolescent CMV Vaccine Sites
Five Tekton sites supported an adolescent cytomegalovirus vaccine study. Recruitment combined targeted digital campaigns, peer referrals, database outreach, and community events, with outreach directed to adolescents and their parents.
-
Meeting Enrollment Two Months Early and Reaching 160% of Goal
At its Austin site, Tekton met the initial enrollment goal for a Phase 2 psoriatic arthritis study two months early. After the sponsor approved overenrollment, the site continued enrolling and … Read more
-
Exceeding the Enrollment Goal for a Phase 3 Social Anxiety Disorder Study
Tekton supported a Phase 3 social anxiety disorder study at two sites through centralized contracting, startup, and recruitment. Tekton Psychiatry Team leaders served as Principal Investigators, and the study’s total … Read more
-
300% of Combined Enrollment Goal Achieved in a Phase 2 Obesity Trial
Tekton’s San Antonio, TX, and Edmond, OK, teams randomized 60 participants in a Phase 2 obesity trial against a combined initial target of 20. Both sites exceeded their individual enrollment … Read more
-
Randomizing 1,500+ Participants for a Phase 3 Flu Vaccine Program
Across seven sites in three states, Tekton centralized startup and recruitment for a Phase 3 influenza vaccine research program. All seven sites exceeded their goals, more than 340 participants were … Read more
-
Over 170% of Enrollment Goal Achieved in a Type 2 Diabetes Study
Tekton’s McKinney, TX, team achieved over 170% of its enrollment goal for a Type 2 diabetes study led by Pablo Mora, MD, FACE, MSc, CDCES.
-
Averaging 170% Enrollment Across Three Type 1 Diabetes Sites
Across three Texas sites, Tekton delivered consistent enrollment and regulatory performance for a Type 1 diabetes trial. All three sites exceeded their targets. Physician-led database review and detailed prescreening helped … Read more
-
One-Day First Participant Visits and Low Screen Fail Rates for a Pneumococcal Study
Tekton delivered a Phase 3 pneumococcal vaccine study at sites in Edmond, Oklahoma, and Austin, Texas, with rapid regulatory and activation timelines. The Edmond site was approved to overenroll and … Read more
-
Rapid Startup and Early Enrollment Completion for a GLP-1 Study
Tekton delivered a Phase 3 GLP-1 medication research study at its Moore, Oklahoma, site. The site moved quickly from startup to enrollment while maintaining a focused, coordinated approach throughout the … Read more
-
156% of Enrollment Goal Delivered for a Diabetes Device Study
Tekton’s McKinney, TX, team achieved 156% of its enrollment goal for a Type 1 and Type 2 diabetes device study led by Pablo Mora, MD, FACE, MSc, CDCES.
-
Rescue Site Achieves 125% of Enrollment Goal in an Alzheimer’s Trial
Tekton’s St. Louis team joined an Alzheimer’s trial as a rescue site and achieved 125% of its enrollment goal. The study team included Ernest Graypel, MD, MHA, Brandon Lenfest, and … Read more
-
Meeting Enrollment Early With 100% Retention in a Phase 2 Migraine Study
At Tekton’s Yukon, Oklahoma site (now Oklahoma City), the team delivered a Phase 2 migraine treatment study with rapid startup, early enrollment completion, full participant retention, and near-perfect diary compliance. … Read more
-
Reaching 108% of Goal Across Seven Phase 3 Norovirus Vaccine Sites
Seven Tekton sites across four states supported a global Phase 3 norovirus vaccine trial involving generally healthy adults. A centralized model aligned startup, regulatory, contracting, budgeting, and recruitment activity across … Read more
-
Enrolling 720+ Participants Across Seven Phase 3 Flu Vaccine Sites
Tekton supported a global Phase 3 influenza vaccine trial across seven sites in three states, centralizing startup, regulatory, and recruitment support. Enrollment was open for two months and focused on … Read more